Trials / Withdrawn
WithdrawnNCT02053883
Cethrin in Acute Cervical Spinal Cord Injury
A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Cethrin in Subjects With Acute Cervical Spinal Cord Injury
- Status
- Withdrawn
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- BioAxone BioSciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 62 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase IIb/III study designed to evaluate the efficacy and safety of Cethrin as a treatment for acute cervical spinal cord injury. During the trial, high and low doses of Cethrin will be compared with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cethrin (BA-210) | High or low doses of Cethrin administered extradurally in a fibrin sealant during spinal decompression/stabilization surgery. |
| DRUG | Placebo | Fibrin sealant alone administered extradurally during spinal decompression/stabilization surgery. |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2016-05-01
- First posted
- 2014-02-04
- Last updated
- 2014-11-26
Source: ClinicalTrials.gov record NCT02053883. Inclusion in this directory is not an endorsement.